Overview

Gender

female

Kristen Hege has served as a member of our board of directors since October 2018. Kristen Hege is currently a Clinical Professor of Medicine, Hematology and Oncology and an attending physician at the University of California, San Francisco (UCSF). She has held a clinical faculty appointment at UCSF since 1997 in the adult hematology and bone marrow transplant program. Kristen Hege has been board-certified in internal medicine, medical oncology and hematology. Kristen Hege received her B.A. summa cum laude from Dartmouth, M.D. from UCSF and completed a medical residency at Brigham & Women’s Hospital, Harvard Medical School and a fellowship in hematology and oncology at UCSF. She serves on the Board of Directors of the Society for Immunotherapy of Cancer, and Mersana Therapeutics and the Strategic Advisory Group for the Parker Institute for Cancer Immunotherapy. In 2015, FierceBiotech recognized her as one of the top 12 women in Biopharma.

Kristen Hege currently serves as Corporate Vice President, Translational Development, Hematology and Oncology and San Francisco site head at Celgene where she is responsible for translational and early clinical development for all hematology and oncology products including small molecules, biologics and cell therapies. Prior to joining Celgene, she served as acting Chief Medical Officer at Aragon Pharmaceuticals, Theraclone Sciences and Cellerant Therapeutics. Kristen Hege began her career at Cell Genesys Inc. where she spent 14 years in various roles of increasing responsibility, ultimately leading the Clinical Research and Development organization.